Characterization of the cholangiocarcinoma drug pemigatinib against FGFR gatekeeper mutants
Pemigatinib is an FDA-approved drug for the treatment of cholangiocarcinoma, but while it is known to target fibroblast growth factor receptors, its mechanism of action is still not fully understood. Here, biochemical and structural analyses reveal that pemigatinib is a potent and selective FGFR1–3...
| Κύριοι συγγραφείς: | , , , , , , , |
|---|---|
| Μορφή: | Άρθρο |
| Γλώσσα: | English |
| Έκδοση: |
Nature Portfolio
2022-08-01
|
| Σειρά: | Communications Chemistry |
| Διαθέσιμο Online: | https://doi.org/10.1038/s42004-022-00718-z |